TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A MedPage Today opinion article by physician Hamayle Saeed describes being screened for diabetes at a BMI of 23 under guidance for Asian Americans but being denied a GLP-1 weight-loss drug at BMI 26.5. The article argues that clinical guidance, drug labels and insurer authorization rules use inconsistent definitions; individual coverage decisions and the broader policy response remain unclear.
Hamayle Saeed, a South Asian physician, says a clinician began screening her for diabetes when her body mass index reached 23, but she was denied a GLP-1 weight-loss drug at a BMI of 26.5. In an October 31 MedPage Today opinion article, Saeed argues the contrast reflects a gap between diabetes-risk guidance for Asian Americans and the higher thresholds used in drug coverage decisions.
Saeed writes that she does not have diabetes and did not meet the BMI criteria she says applied to her request: 30 for obesity, or 27 with a weight-related condition. Those figures are common eligibility thresholds cited in clinical trial criteria and payer authorization policies, but they do not establish that every insurer or plan uses identical rules. The article does not identify her insurer or provide its written denial.
The piece points to differences in body composition and disease risk as a reason standard BMI cutoffs may not apply equally across populations. Saeed cites the World Health Organization’s lower action points for Asian populations, BMI 23 and 27.5, and a study of nearly 1.5 million adults in England that estimated South Asian adults reached the diabetes risk seen in white adults at BMI 30 at a BMI of 23.9. These are population-level findings, not an individual diagnosis or a guarantee of drug eligibility.
Saeed also cites a 2025 trial, STEP 11, conducted in South Korea and Thailand. Participants with BMI of at least 25 who received semaglutide 2.4 mg lost an average of 16% of body weight, compared with 3.1% among placebo participants, according to the article. In a post hoc subgroup of 68 participants who began below BMI 30, the reported losses were 17.6% for semaglutide and 4.4% for placebo. The subgroup analysis does not by itself determine how U.S. insurers should cover treatment.
How BMI Rules Shape Drug Access
The dispute matters because screening thresholds and treatment coverage rules serve different purposes, yet patients may encounter both as measures of whether their weight-related health risks warrant care. A lower threshold can prompt earlier risk assessment without automatically creating access to a prescription drug. Saeed’s account shows how that distinction may be experienced by a patient whose risk is assessed using one standard but whose coverage request is judged using another.
The article also describes a policy backdrop in which public insurance coverage for weight-loss GLP-1s has contracted. Saeed says Medi-Cal dropped weight-loss coverage in January and MassHealth followed in July; the article does not detail plan-specific exceptions or the effects on individual patients. If coverage becomes narrower, people who do not meet conventional BMI cutoffs may face additional barriers, though the scale of that effect is not quantified here.
At issue is not simply whether a particular BMI number should replace another. Clinicians, regulators and payers must weigh evidence about risk and treatment outcomes against trial populations, approved indications, costs and coverage policy. Saeed argues Asian-specific measures should inform those decisions; the opinion article does not establish a new national coverage standard.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Therabody Theragun Relief Massage Gun, 3-Speed, Navy
Fitbit Sense 2 Health and Fitness Smartwatch (Lunar White/Platinum)
As an affiliate, we earn on qualifying purchases.
The Standards Behind the Dispute
Saeed’s account brings together several standards that are related but not interchangeable. Diabetes screening guidance can recommend when to test for disease risk. A drug’s FDA-approved labeling describes the population for which it is indicated, while an insurer’s prior authorization form sets conditions for payment. Clinical guidance, labeling and reimbursement policy can therefore differ, and meeting one threshold does not necessarily satisfy the others.
The article says revised 2026 labels for Wegovy (semaglutide) and Zepbound (tirzepatide) describe treatment for adults with obesity, or overweight with a weight-related condition, without stating a numerical BMI in the indication. Saeed says payer forms and trial descriptions continue to rely on BMI values of 30 or 27. The exact wording and requirements can vary by product, indication and insurer; readers should not assume one policy applies across all plans.
Saeed cites a 2026 analysis of 352 GLP-1 trials, reporting that a BMI cutoff of 30 made 41.5% of non-Asian American adults, 13.5% of Asian Americans and 7.2% of Korean adults eligible under the analysis. The figures describe trial eligibility under the analyzed cutoff, not rates of treatment or coverage in the general population. She also notes that the American Diabetes Association’s 2026 Standards of Care call for ethnicity-appropriate cutoffs when assessing excess adiposity.
“The ADA guideline that flags me for annual diabetes screening and the prior authorization form that denies me the drug are describing the same 26.5. Only one of them was written with an Asian body in mind.”
— Hamayle Saeed, MD, in a MedPage Today opinion article
What Coverage Rules Still Differ
The article does not name Saeed’s insurer, reproduce the denial, or clarify whether her request was evaluated under a particular product label, plan policy or medical-benefit rule. It is also unclear whether an appeal was filed or whether other clinical factors affected the decision. Her experience is a first-person account and should not be treated as proof of how every insurer handles Asian patients.
The cited studies and guidance do not settle whether lower BMI thresholds should automatically trigger GLP-1 coverage. The article does not provide a national estimate of how many Asian Americans are denied treatment under current criteria, nor does it establish the cost or health effects of changing those criteria. The scope and terms of Medi-Cal and MassHealth coverage changes may also vary by plan and circumstance.
Coverage Decisions and Policy Review
The next steps are likely to depend on how clinicians, insurers and public agencies interpret the evidence and the wording of current drug labels. Patients seeking coverage will still need to check the rules for their specific plan and indication; the article does not announce a new insurer policy, regulatory action or scheduled decision.
Further research could test whether population-specific BMI thresholds predict treatment benefit and safety across different Asian communities, and whether adjusting coverage criteria changes access or outcomes. For now, Saeed’s report documents a policy tension rather than a resolution: diabetes screening may account for elevated risk at lower BMI, while authorization requirements can continue to rely on higher cutoffs.
Key Questions
What happened in the report?
Hamayle Saeed wrote that she was screened for diabetes at BMI 23 under guidance relevant to Asian Americans but was denied a GLP-1 weight-loss drug at BMI 26.5. Her article uses her experience to discuss differences between risk guidance and coverage criteria.
Does a BMI of 23 qualify someone for a GLP-1 drug?
Not on the information in this report. A diabetes-screening threshold does not automatically establish eligibility for a drug or insurance coverage. Product indications and plan authorization rules may differ.
Why does the article discuss different BMI thresholds for Asian adults?
Saeed cites guidance and research indicating that some Asian populations can face elevated diabetes risk at lower BMI values. These population-level measures do not diagnose an individual or set a universal treatment rule.
Did the article establish that all insurers deny coverage below BMI 30?
No. The article describes Saeed’s denial and discusses common thresholds, but it does not identify her insurer or document every plan’s requirements. Coverage depends on the specific plan, medicine and indication.
Source: medpagetoday.com
